Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06053658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Nov 1, 2026 → Nov 1, 2028
See other at-risk trials from M.D. Anderson Cancer Center

Record History

  1. Primary completion pushed from Nov 1, 2026 to Nov 1, 2028 Eligibility criteria expanded, about 42 words · Study description expanded, about 4 words Show 2 more changesShow less
    • Eligibility criteria expanded, about 42 words
    • Study description expanded, about 4 words
  2. Study sites: 5 to 6v14
  3. 2 versions Re-verified since Mar 9, 2026, no change to tracked fieldsv12-v13
  4. Study sites: 3 to 5v11
  5. 2 versions Re-verified since Jul 2, 2025, no change to tracked fieldsv9-v10
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 1 to 3v8
  2. 2 versions Re-verified since Aug 26, 2024, no change to tracked fieldsv6-v7
  3. Eligibility criteria expanded, about 29 wordsv5 See this version in full on ClinicalTrials.gov ↗
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 31, 2024 to Jan 5, 2024 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Jan 31, 2024 to Jan 5, 2024
    • Site details revised
  6. Enrollment target: 10 to 48 Primary endpoint revisedv2 Show 1 more changeShow less
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Trial Details
NCT Number NCT06053658
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: AVEO Pharmaceuticals, Inc.
Conditions Renal Cell Carcinoma
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov